Progyny (PGNY) Raises 2026 Guidance Midpoint After Q3 Revenue Grows 8.9%
1 min read
Q3 revenue was $341.3M, up 8.9% from $313.3M a year earlier; net income was $26.3M versus $13.9M. Progyny raised the midpoint of full-year 2026 guidance; revised figures were not stated in the release text.
Material Details
| # | Detail | AI Analyst View |
|---|---|---|
| 1 | Revenue $341.3M vs. $313.3M, up 8.9% | Revenue growth was driven by increases in clients and covered lives, providing the clearest read on demand. |
| 2 | Net income $26.3M vs. $13.9M | Profit nearly doubled year over year; the release attributes the increase primarily to higher gross profit and lower stock-based compensation. |
| 3 | Gross profit $83.7M vs. $72.8M, up 15% | Gross profit grew faster than revenue; gross margin also expanded to 24.5% from 23.2%. |
| 4 | Adjusted EBITDA $58.4M vs. $55.0M, up 6.3% | Growth lagged revenue, and margin fell to 17.1% from 17.5% as platform investments partly offset higher gross profit. |
| 5 | Raised midpoint of full-year 2026 guidance | An upward revision supports the near-term outlook, but revised guidance figures were not stated in the release text. |
| 6 | Repurchased nearly 3M shares for $82.7M | The release gives no prior-period comparison; buybacks support per-share results but use cash. |
Context by AI Analyst
This is a quarterly results update with strong year-over-year profit growth, an upward guidance midpoint revision, and continued share repurchases. The next catalyst is the full-year 2026 guidance figures and the company's year-end results, expected in February.
Based on the original press release from Progyny, Inc. distributed by GlobeNewswire.
This is an AI-generated summary and may contain inaccuracies. Summary is based on content distributed by GlobeNewswire. Please verify any important information with the original source. This information is not a recommendation for what you should do personally and does not constitute investment advice.